Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 9/20 | 0.83 |
| ▸ | SSTR2 | P30874 | 14/20 | 0.80 |
| ▸ | SSTR5 | P35346 | 10/20 | 0.80 |
| ▸ | SSTR3 | P32745 | 2/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1651014 | 1.00 | SSTR4 (0.83) | SSTR4SSTR2SSTR5SSTR3 | |
| SCHEMBL180440 | 1.00 | SSTR4 (0.83) | SSTR4SSTR2SSTR5SSTR3 | |
| SCHEMBL5069978 | 0.99 | SSTR4 (0.82) | SSTR4SSTR2SSTR5SSTR3 | |
| SCHEMBL29449384 | 0.99 | SSTR4 (0.82) | SSTR4SSTR2SSTR5SSTR3 | |
| SCHEMBL29408685 | 0.97 | SSTR4 (0.79) | SSTR4SSTR2SSTR5SSTR3 | |
| SCHEMBL29360979 | 0.95 | SSTR4 (0.78) | SSTR4SSTR2SSTR5SSTR3 | |
| SCHEMBL29653935 | 0.95 | SSTR2 (0.79) | SSTR4SSTR2SSTR5SSTR3 | |
| SCHEMBL23482744 | 0.91 | SSTR2 (0.88) | SSTR4SSTR2SSTR5SSTR3 | |
| SCHEMBL23901126 | 0.91 | SSTR2 (0.88) | SSTR4SSTR2SSTR5SSTR3 | |
| SCHEMBL24064978 | 0.91 | SSTR2 (0.83) | SSTR4SSTR2SSTR5SSTR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260069726-A1 | ZWITTERIONIC COMPOUNDS AND USES THEREOF | UNIV SASKATCHEWAN (CA) | 2026-03-12 | — | — | US | disclosed |
| EP-4580686-A1 | HALOGENATED SOMATOSTATIN ANALOGS WITH MULTIPLE SOMATOSTATIN RECEPTOR SUBTYPE SELECTIVITY | Grafton Therapeutics Sàrl (CH) | 2025-07-09 | — | — | EP | disclosed |
| CN-118812656-B | Iodine-131 marked small molecular polypeptide TCMP-Y1 and preparation method and application thereof | 广州港湾医疗器械有限公司 | 2025-03-04 | — | — | CN | disclosed |
| WO-2025002409-A1 | USE OF 212PB-DOTATATE IN PREPARATION OF DRUG FOR TREATMENT OF GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR WITH POSITIVE SOMATOSTATIN RECEPTOR | 北京先通国际医药科技股份有限公司 | 2025-01-02 | — | — | WO | disclosed |
| CN-119013051-A | Composition treatment of small cell lung cancer | 同位素技术慕尼黑有限公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-118812656-A | Iodine-131 marked small molecular polypeptide TCMP-Y1 and preparation method and application thereof | 广州港湾医疗器械有限公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-113164778-B | Pharmaceutical combinations of anti-CEACAM 6 and TIM3 antibodies | 拜耳公司 | 2024-07-26 | — | — | CN | disclosed |
| US-20240165282-A1 | CONFORMATIONAL CONSTRAINED SOMATOSTATIN RECEPTOR 3 PEPTIDE LIGANDS AND THEIR CONJUGATES AND USES THEREOF | STARGET PHARMA LTD. (IL) | 2024-05-23 | — | — | US | disclosed |
| CN-118045208-A | Preparation method of fluorine-18 aluminum fluoride marked NOTA-octreotide | 中国人民解放军总医院第一医学中心 | 2024-05-17 | — | — | CN | disclosed |
| WO-2024047112-A1 | HALOGENATED SOMATOSTATIN ANALOGS WITH MULTIPLE SOMATOSTATIN RECEPTOR SUBTYPE SELECTIVITY | SOMTHERANOSTICS SARL (CH) | 2024-03-07 | — | — | WO | disclosed |
| WO-2023208341-A1 | COMBINATION TREATMENT OF SMALL-CELL LUNG CANCER | ITM Isotope Technologies Munich SE (DE) | 2023-11-02 | — | — | WO | disclosed |
| CN-116981487-A | Combination of para-aminohippuric acid (PAH) and radiolabeled complexes for the treatment of cancer | 同位素技术慕尼黑有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116806144-A | Stable formulations of radionuclide complexes | ITM索卢钦股份有限公司 | 2023-09-26 | — | — | CN | disclosed |
| CN-116806212-A | Method for purifying radiolabeled large particle aggregated human serum albumin | 特拉西斯股份有限公司 | 2023-09-26 | — | — | CN | disclosed |
| WO-2023038927-A1 | BLADDER CANCER THERAPIES | AURA BIOSCIENCES, INC. (US) | 2023-03-16 | — | — | WO | disclosed |
| WO-2022218640-A1 | RADIOPHARMACEUTICALS AT DIFFERENT ACTIVITY REFERENCE TIMES | ITM Isotope Technologies Munich SE (DE) | 2022-10-20 | — | — | WO | disclosed |
| WO-2022185315-A1 | CONFORMATIONAL CONSTRAINED SOMATOSTATIN RECEPTOR 3 PEPTIDE LIGANDS AND THEIR CONJUGATES AND USES THEREOF | STARGET PHARMA LTD. (IL) | 2022-09-09 | — | — | WO | disclosed |
| WO-2022161897-A1 | METHOD FOR PURIFYING RADIOLABELLED HUMAN SERUM ALBUMIN MACROAGGREGATES | TRASIS S.A (BE) | 2022-08-04 | — | — | WO | disclosed |
| EP-3965751-A1 | PARA-AMINOHIPPURIC ACID (PAH) AS A RENAL PROTECTIVE SUBSTANCE | ITM Isotope Technologies Munich SE (DE) | 2022-03-16 | — | — | EP | disclosed |
| EP-3503929-B1 | RAPID ISOLATION OF CYCLOTRON-PRODUCED GALLIUM-68 | MAYO FOUND MEDICAL EDUCATION & RES (US) | 2022-02-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240165282-A1 | CONFORMATIONAL CONSTRAINED SOMATOSTATIN RECEPTOR 3 PEPTIDE LIGANDS AND THEIR CONJUGATES AND USES THEREOF | SSTR3, SSTR4, SSTR5 | SSTR4 2/4885SSTR2 5/4885SSTR5 3/4885 |
| US-20260069726-A1 | ZWITTERIONIC COMPOUNDS AND USES THEREOF | CA13, SLCO2B1, SLCO2A1 | SSTR4 78/4885SSTR2 80/4885SSTR5 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.